Scroll

auranofin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4122	34031-32-8

Description:

Molecule	Description
Synonyms: auranofin ridaura	An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious. Molecular weight: 678.48 Formula: C20H34AuO9PS CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

auranofin
ridaura

An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.

Molecular weight: 678.48
Formula: C20H34AuO9PS
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
6	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	60 %	Benet LZ, Broccatelli F, Oprea TI

Approvals:

Date	Agency	Company	Orphan
May 24, 1985	FDA	PROMETHEUS LABS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M01CB03	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS SPECIFIC ANTIRHEUMATIC AGENTS Gold preparations
CHEBI has role	CHEBI:35705	immunosuppressive agents
CHEBI has role	CHEBI:35842	anti-rheumatic drugs
CHEBI has role	CHEBI:64670	thioredoxin reductase (NADPH) inhibitors
MeSH PA	D018501	Antirheumatic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Rheumatoid arthritis	indication	69896004	DOID:7148
Psoriasis with arthropathy	off-label use	33339001
Felty's syndrome	off-label use	57160007	DOID:11042
Juvenile rheumatoid arthritis	off-label use	410795001
Necrotizing enterocolitis in fetus OR newborn	contraindication	2707005
Hypertensive disorder	contraindication	38341003	DOID:10763
Eczema	contraindication	43116000
Chronic heart failure	contraindication	48447003
Fibrosis of lung	contraindication	51615001	DOID:3770
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Colitis	contraindication	64226004	DOID:0060180
Diabetes mellitus	contraindication	73211009	DOID:9351
Sjögren's syndrome	contraindication	83901003	DOID:12894
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Urticaria	contraindication	126485001
Inflammatory disease of liver	contraindication	128241005
Disease of blood AND/OR blood-forming organ	contraindication	191124002	DOID:74
Disease of liver	contraindication	235856003	DOID:409
Eruption of skin	contraindication	271807003	DOID:0050486
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Ultraviolet light therapy	contraindication	363695005
Erythroderma	contraindication	399992009
Severe Debilitation	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.48	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.44	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.65	DRUG MATRIX
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	6.22	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	6.02	DRUG MATRIX
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	6.41	DRUG MATRIX
Arachidonate 5-lipoxygenase	Enzyme	P09917	LOX5_HUMAN				WOMBAT-PK
Thioredoxin reductase 1, cytoplasmic	Enzyme	Q16881	TRXR1_HUMAN				WOMBAT-PK
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.92	DRUG MATRIX
Transient receptor potential cation channel subfamily A member 1	Ion channel	O75762	TRPA1_HUMAN	ACTIVATOR	EC50	6	IUPHAR

External reference:

ID	Source
4018014	VUID
N0000146358	NUI
D00237	KEGG_DRUG
4018014	VANDF
C0004320	UMLSCUI
CHEBI:2922	CHEBI
CHEMBL1366	ChEMBL_ID
D001310	MESH_DESCRIPTOR_UI
DB00995	DRUGBANK_ID
6306	IUPHAR_LIGAND_ID
3972	INN_ID
3H04W2810V	UNII
24199313	PUBCHEM_CID
1227	RXNORM
1189	MMSL
4231	MMSL
d00818	MMSL
002398	NDDF
18002004	SNOMEDCT_US
387100001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
RIDAURA	HUMAN PRESCRIPTION DRUG LABEL	1	54766-093	CAPSULE	3 mg	ORAL	NDA	23 sections
RIDAURA	HUMAN PRESCRIPTION DRUG LABEL	1	65483-093	CAPSULE	3 mg	ORAL	NDA	23 sections